SAB Biotherapeutics Inc (NASDAQ:SABS) — Market Cap & Net Worth
Market Cap & Net Worth: SAB Biotherapeutics Inc (SABS)
SAB Biotherapeutics Inc (NASDAQ:SABS) has a market capitalization of $257.21 Million ($257.21 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15643 globally and #3639 in its home market, demonstrating a 7.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SAB Biotherapeutics Inc's stock price $3.66 by its total outstanding shares 70275714 (70.28 Million). Review how much debt does SAB Biotherapeutics Inc carry to assess the company's total debt and financial obligations.
SAB Biotherapeutics Inc Market Cap History: 2021 to 2026
SAB Biotherapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $5.49 Billion to $257.21 Million (-46.26% CAGR).
Index Memberships
SAB Biotherapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.01% | #420 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1511 of 3165 |
Weight: SAB Biotherapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
SAB Biotherapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SAB Biotherapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
201.63x
SAB Biotherapeutics Inc's market cap is 201.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $5.49 Billion | $60.88 Million | -$17.14 Million | 90.16x | N/A |
| 2022 | $414.63 Million | $23.90 Million | -$18.74 Million | 17.35x | N/A |
| 2023 | $483.50 Million | $2.24 Million | -$42.19 Million | 215.94x | N/A |
| 2024 | $266.64 Million | $1.32 Million | -$34.11 Million | 201.63x | N/A |
Competitor Companies of SABS by Market Capitalization
Companies near SAB Biotherapeutics Inc in the global market cap rankings as of June 17, 2026.
Key companies related to SAB Biotherapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
SAB Biotherapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, SAB Biotherapeutics Inc's market cap moved from $5.49 Billion to $ 257.21 Million, with a yearly change of -46.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $257.21 Million | -2.14% |
| 2025 | $262.83 Million | -1.43% |
| 2024 | $266.64 Million | -44.85% |
| 2023 | $483.50 Million | +16.61% |
| 2022 | $414.63 Million | -92.45% |
| 2021 | $5.49 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of SAB Biotherapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $257.21 Million USD |
| MoneyControl | $257.21 Million USD |
| MarketWatch | $257.21 Million USD |
| marketcap.company | $257.21 Million USD |
| Reuters | $257.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes … Read more